Cadence Neuroscience Names CEO for Clinical Trial Launch

REDMOND, Wash., Sept. 22, 2026 /CourierPR/ -- Cadence Neuroscience, a clinical-stage company developing a biomarker-guided platform for personalized neuromodulation, has appointed Chris Cronin as its new Chief Executive Officer (CEO). The appointment comes as the company prepares for the clinical evaluation of its investigational Biomarker Targeted Stimulation (BTS) system in focal drug-resistant epilepsy, its first indication. Chris Cronin, a veteran medtech executive with nearly three decades of experience, will lead Cadence through this critical phase of development, while founder Kent Leyde will continue to serve as Chief Technology Officer (CTO).

Cronin's extensive background in medical technology, healthcare, finance, and business development will be instrumental in guiding Cadence through this significant phase of clinical evaluation. His most recent role was as CEO and President of KARDION, where he led the organization through a critical stage of growth as it moved from first-in-human trials to pivotal studies. Prior to KARDION, Cronin held leadership roles at MOBĒ and Medtronic, including a decade at the latter, where he held P&L responsibility across eight countries and regions for one of Medtronic's largest franchises, spanning modalities such as deep brain stimulation, spinal cord stimulation, and intrathecal baclofen.

Cronin's appointment follows the company's initial focus on the investigational BTS system, designed to use patient-specific neural biomarkers to inform stimulation and measure the brain's response to therapy in real time. This biomarker-guided approach is intended to provide clinicians and researchers with real-time physiological feedback that may support more personalized and adaptable neuromodulation. The company's initial clinical evaluation of the BTS system is set to begin in focal drug-resistant epilepsy, a serious condition in which many patients continue to experience seizures despite available anti-seizure medications and may have limited treatment options. This substantial unmet need makes focal drug-resistant epilepsy an important first indication for the clinical evaluation of Cadence's platform.

Cronin's patient-centered approach to healthcare and medical devices aligns closely with Cadence's founding ethos. As CEO, he will work alongside Kent Leyde, who continues to lead Cadence's technology development, product strategy, and external collaborations.

Cadence's investigational BTS system is designed to use patient-specific neural biomarkers to inform stimulation and measure the brain's response to therapy in real time. The company is initially evaluating the BTS system in focal drug-resistant epilepsy, with a long-term goal of developing the platform for additional neurological conditions. The technology originated from research conducted by a Mayo Clinic Neurology and Neurosurgery team led by Gregory Worrell, a Mayo Clinic epileptologist and lead investigator. Cadence is building on this scientific foundation as it advances the BTS system through clinical evaluation.

Cadence Neuroscience is a clinical-stage medical technology company developing a biomarker-guided platform for personalized neuromodulation. Its investigational BTS system is designed to use patient-specific neural biomarkers to inform stimulation and measure the brain's response to therapy in real time. The company is initially advancing the BTS system in focal drug-resistant epilepsy, with a long-term goal of developing the platform for additional neurological conditions. Founded in 2017 and headquartered in Redmond, Washington, Cadence is backed by leading healthcare and technology investors, including F-Prime Capital, Jazz Venture Partners, LivaNova, Angelini Lumira Biosciences Fund, and Mayo Clinic. For more information, visit cadenceneuro.com.